NCT03264157View on ClinicalTrials.gov

Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

December 8, 2017

Primary Completion Date

March 2, 2018

Study Completion Date

July 13, 2018

Conditions
Healthy
Interventions
DRUG

HRIG

A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.

DRUG

HyperRAB

A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.

BIOLOGICAL

RabAvert

A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.

Trial Locations (2)

27612

Wake Research Associates, Raleigh

55114

Prism Research, Saint Paul

Sponsors
All Listed Sponsors
lead

Bio Products Laboratory

OTHER